title: Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium.
abstract: In the process of angiogenesis, endothelial adhesion molecules play a significant role in vascular morphogenesis, in coordination with angiogenic factor signaling. Here we report that a novel angiogenesis inhibitor, E7820 (an aromatic sulfonamide derivative), inhibited in vitro proliferation and tube formation of human umbilical vascular endothelial cell (HUVEC). E7820 decreased integrin alpha2, 3, 5, and beta1 in confluent culture of HUVEC, and integrin alpha2 was initially suppressed in mRNA level, followed by decrement of integrins alpha3, 5, and beta1. The inhibition of integrin alpha2 expression in HUVEC showed dose dependence but did not alter the level of CD31. Up-regulation of integrin alpha2 by phorbol 12-myristate 13-acetate abrogated the inhibitory effect of E7820 on tube formation within type I collagen gel, whereas addition of antibody against integrin alpha2 canceled the phorbol 12-myristate 13-acetate effect. These results suggest that E7820 inhibited tube formation through the suppression of integrin alpha2. Oral administration of E7820 remarkably resulted in inhibition of tumor-induced angiogenesis in mouse dorsal air sac model, and tumor growth of human colorectal tumor cell lines (WiDr and LoVo) was inhibited in xenotransplanted model in mice. This is the first time that a small molecule has been shown to modulate integrins, and this finding may provide the basis for a new approach to antiangiogenic therapy through the suppression of integrin alpha2 on endothelium.
authors.affiliation: Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan 300-2635.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Funahashi
authors.forename: Naoko Hata
authors.initials: NH
authors.lastname: Sugi
authors.forename: Taro
authors.initials: T
authors.lastname: Semba
authors.forename: Yuji
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Shinichi
authors.initials: S
authors.lastname: Hamaoka
authors.forename: Naoko
authors.initials: N
authors.lastname: Tsukahara-Tamai
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Ozawa
authors.forename: Akihiko
authors.initials: A
authors.lastname: Tsuruoka
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Nara
authors.forename: Keiko
authors.initials: K
authors.lastname: Takahashi
authors.forename: Tadashi
authors.initials: T
authors.lastname: Okabe
authors.forename: Junichi
authors.initials: J
authors.lastname: Kamata
authors.forename: Takashi
authors.initials: T
authors.lastname: Owa
authors.forename: Norihiro
authors.initials: N
authors.lastname: Ueda
authors.forename: Toru
authors.initials: T
authors.lastname: Haneda
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yonaga
authors.forename: Kentaro
authors.initials: K
authors.lastname: Yoshimatsu
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Wakabayashi
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D002455:Cell Division / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000098:blood supply / Q000188:drug therapy; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D039421:Integrin alpha2 / Q000096:biosynthesis*; D051379:Mice; D008819:Mice, Nude; D013449:Sulfonamides / Q000494:pharmacology*; D023041:Xenograft Model Antitumor Assays
chemical_list: D020533:Angiogenesis Inhibitors; D007211:Indoles; D039421:Integrin alpha2; D013449:Sulfonamides; C468872:N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide